Перспективы развития фундаментальных наук

Abstract

In this study, we conducted an in vitro study comparing the potential of targeted therapeutic drugs containing a cytotoxic agent mc-DM1. The therapeutic potential of using an HER2-targeting Affibody molecule fused to an albumin-binding domain (ABD) to increase half-life and conjugated to the cytotoxic maytansine derivative, MC-DM1, has previously been confirmed. In this study, we also investigated the potential of a targeted therapeutic conjugate that includes an Affibody molecule targeting HER2 and the cytotoxic agent MC-DM1, and the PAS600 polypeptide was the hallmark of the drug design. PAS polypeptides represent a novel class of biosynthetic polymers comprising repetitive sequences of the small proteinogenic amino acids L-proline, L-alanine and/or L-serine. In this study, PAS600 used to increase the half-life of the drug. We conducted in vitro studies comparing the potential of the new (HE)3-ZHER2-Cys/DM1-PAS600 variant molecule with the previously studied (HE)3-ZHER2-ABD-Cys/DM1 molecule